The authors performed longitudinal analyses of the plasma from 22 ALK-positive NSCLC patients with acquired resistance to ALK TKIs to track the evolution of drug resistance during the treatment course and observed that ALK mutations emerged and disappeared during the sequential administration of ALK TKIs. The gene discussed is ALK; the disease is non-small cell lung carcinoma.